KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.

ABSTRACT:

Backgrounds

Immune checkpoint blockade has revolutionized cancer treatment and has improved the survival of a subset of patients with cancer. However, numerous patients do not benefit from immunotherapy, and treatment resistance is a major challenge. Krüppel-like factor 12 (KLF12) is a transcriptional inhibitor whose role in tumor immunity is unclear.

Methods

We demonstrated a relationship between KLF12 and CD8⁺ T cells in vivo and in vitro by flow cytometry. The role and underlying mechanism that KLF12 regulates CD8⁺ T cells were investigated using reverse transcription and quantitative PCR, western blot FACS, chromatin immunoprecipitation-PCR and Dual-Luciferase reporter assays, etc, and employing small interfering RNA (siRNA) and inhibitors. In vivo

SUBMITTER: Zheng Y 

PROVIDER: S-EPMC10432659 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature